Keysight Technologies enters the first week of June having given back some of the post-earnings momentum, with the stock slipping 2.6% on the week to $346.57 — even after a sharp 5% single-day rebound on June 2 that arrested the slide.
The options market tells the clearest story about the shift in tone. After the put/call ratio dropped into deeply bullish territory last week — running nearly 1.4 standard deviations below its 20-day average — it has since drifted back up to 0.79. That's still below the 20-day mean of 0.95, so options traders remain net more constructive than they were through April and early May, but the extreme bullish skew from immediately post-earnings has faded. The 52-week range runs from 0.62 at the bullish extreme to 1.59 at the defensive peak; at 0.79, positioning is mildly constructive rather than charged. The direction of travel — from 0.62 on May 19 back toward the mean — suggests some of the call-side enthusiasm built around the earnings beat is being pared.
Short interest carries almost no weight as a story here. At 1.2% of the free float, the short position is genuinely small, and it actually fell 8.4% over the week — a modest unwind rather than any notable escalation. Borrow conditions confirm the picture: cost to borrow has collapsed to 0.16%, down from 0.37% a week ago and more than 70% below where it was a month ago. Availability is essentially uncapped — shares available to borrow are running at multiples of the existing short interest — so there is no lending-market tension worth flagging. This is a story about what bulls are doing, not what bears are building.
The Street remains firmly in the bull camp, and the earnings print two weeks ago hardened that view. The consensus mean target is $383, roughly 10% above the current price. That target was reset comprehensively in the days following May 19 results: JP Morgan held Overweight at $390, Citi Buy at $396, UBS Buy at $420, Susquehanna Positive at $425. Even Truist's lone Hold came with a target raise from $310 to $376 — a 21% lift on a neutral rating. Morgan Stanley's equal-weight at $350 remains the floor of the post-earnings range, and at $346.57 the stock has now dipped fractionally below that marker. EPS momentum factor scores are strong — ranking in the 87th percentile on 30-day momentum and the 72nd on 90-day momentum — which reflects the earnings beat doing real fundamental work. Valuation is not cheap at roughly 32x trailing earnings, with EV/EBITDA near 26x, but the multiple has compressed modestly over the past month as the price pulled back.
Insider activity has been one-directional but not alarming. The CEO sold 500 shares in mid-May and made additional sales in March, while the CFO and General Counsel also sold in March. Net selling across all insiders over the past 90 days totals around $11.5 million. All trades are small relative to the float and carry low significance scores — the pattern looks more like routine vesting-related activity than conviction selling.
The next scheduled catalyst is the Q3 earnings call on August 18. Between now and then, the degree to which the stock can hold above — or recover — Morgan Stanley's $350 equal-weight target will be worth watching, particularly as options positioning continues its drift back toward the 20-day average.
See the live data behind this article on ORTEX.
Open KEYS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
